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Certain drugs evidently exert their therapeutic effects via
sodium channel inhibition: local anesthetics, class I
antiarrhythmics and certain anticonvulsants. Novel
sodium channel inhibitor compounds are actively investi-
gated for other indications involving stroke, ischemia, var-
ious neurodegenerative conditions and pain syndromes.
All these drugs cause voltage- and use-dependent inhibi-
tion of sodium channels. However, biophysical properties
of inhibition can differ widely even between use-depend-
ent sodium channel inhibitors which seem to act simi-
larly. Recently it has been proposed that the mechanism
of inhibition can be more important than potency or iso-
form selectivity regarding the therapeutical potential of
the drugs (e.g. [1]). One important question is which con-
formational state is preferred by the drug. In this study we
attempted to discriminate preference to fast- vs. slow-inac-
tivated conformations. Slow association to fast-inacti-
vated state and fast association to slow-inactivated state
cannot be distinguished using traditional protocols. We
have recently developed a protocol to test fast- vs. slow-
inactivated state preference using electrophysiology only,
i.e. without mutagenesis or enzymatic treatment experi-
ments. We tested 28 use-dependent sodium channel
inhibitors of different chemical structure and therapeutic
indication using this protocol, and found that the mecha-
nisms primarily overlap with the latter.
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